Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis.
Adherence to oral daily bisphosphonate regimens in postmenopausal osteoporosis is currently suboptimal. Less frequent dosing regimens are likely to improve patient adherence and thus, potentially, patient outcomes. A multicenter, randomized, double-blind, noninferiority study was conducted in 235 wo...
Главные авторы: | Cooper, C, Emkey, R, McDonald, R, Hawker, G, Bianchi, G, Wilson, K, Schimmer, R |
---|---|
Формат: | Journal article |
Язык: | English |
Опубликовано: |
2003
|
Схожие документы
-
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
по: Reginster, J, и др.
Опубликовано: (2006) -
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
по: Miller, P, и др.
Опубликовано: (2005) -
Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.
по: Pazianas, M, и др.
Опубликовано: (2010) -
Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
по: Bauss, F, и др.
Опубликовано: (2004) -
Pathogenesis and treatment of postmenopausal osteoporosis
по: Milhaud, G, и др.
Опубликовано: (1983)